Concerns raised over 10% vaccine export clause at TRIPS meet
Sources said discussions on the proposal will continue as some countries like the UK said the proposal is not endorsed by any member and it is unclear how a dialogue can be established in such case.

The meeting was held to discuss a proposal floated by India, South Africa, the US and the EU to waive patents on Covid-19 vaccines.
Sources said discussions on the proposal will continue as some countries like the UK said the proposal is not endorsed by any member and it is unclear how a dialogue can be established in such case.
"Most members said they needed more time to consult the document internally before engaging in substantive discussions," said a Geneva-based official.
As per the proposal, developing countries which exported more than 10% of world exports of Covid-19 vaccine doses in 2021 are not eligible for the waiver. The proposed solution also limits the product scope to vaccines with a commitment to decide on the extension of the solution to therapeutics and diagnostics within six months from the date of the decision on vaccines.
The proposal also allows eligible members to issue a single authorisation to use the subject matter of multiple patents, export the vaccines and supply to regional or international initiatives such as Covax.

According to sources, several delegations said the proposal is deficient regarding other crucial elements of the Covid-19 response such as therapeutics, diagnostics and transfer of technology, which are equally important to combat the pandemic in a holistic manner.
South Africa favoured a solution-oriented mode to reach an outcome before MC12 by engaging in text-based negotiations.
"It said many members have been demanding for months the waiver request from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of Covid-19," the official said.
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.